Regeneron Fails to Block Amgen’s Eylea Biosimilar During Appeal

Regeneron Pharmaceuticals Inc. failed to block Amgen Inc.'s biosimilar of Eylea while it appeals a West Virginia federal judge’s denial of Regeneron’s request for a preliminary injunction, though the Federal Circuit said it will expedite the proceeding.

A three-judge panel of the US Court of Appeals for the Federal Circuit denied Regeneron’s bid to block Amgen from launching Pavblu, its biosimilar of the blockbuster eye-disease drug, pending Regeneron’s appeal, according to an order issued Tuesday. Shares of Regeneron dropped by as much 5.1% in the wake of the ruling.

• “Without prejudicing the ultimate disposition of the issues on appeal, we ...